2023-505434-98-00
Completed
Phase 1
A Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion (SSD) Formulation in Adult Subjects with Impaired Hepatic Function
Salix Pharmaceuticals Inc.1 site in 1 country18 target enrollmentStarted: October 13, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Salix Pharmaceuticals Inc.
- Enrollment
- 18
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Bausch Health
Scientific
Salix Pharmaceuticals Inc.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma2025-522307-14-00Intas Pharmaceuticals Limited19
Completed
Phase 1
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
Active, not recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45
Not yet recruiting
Phase 1
A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants2024-516261-36-00Cinclus Pharma Holding AB (publ)113
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44